GlassScriptPhysician profile
Paul Zolty
NPI 1033117940
$2,222.63
in general payments reported to CMS, 2019-2025
23 companies · $893 in 2025
The $893 reported for 2025 was more than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
See the full distribution for Sleep Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.67 · 2020: $172 · 2021: $120 · 2022: $85.22 · 2023: $463 · 2024: $442 · 2025: $893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,538 · Education: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,537.67 |
| Education | $259.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $572.26 | 2023-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $417.04 | 2021-2025 | |
| Glaxosmithkline, LLC. | $242.72 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Itamar Medical INC | $160.36 | 2023-2025 | Watchpatone |
| Harmony Biosciences LLC | $152.20 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $126.14 | 2019-2025 | Fasenra |
| Insmed, INC. | $103.46 | 2023-2024 | Arikayce |
| Lilly USA, LLC | $60.90 | 2025 | Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $51.70 | 2022-2023 | |
| Zoll Respicardia, INC. | $38.93 | 2024 | Remede System |
| Avadel Cns Pharmaceuticals, LLC | $34.74 | 2023 | Lumryz |
| Actelion Pharmaceuticals US, INC. | $32.62 | 2020-2024 | Uptravi, Opsumit |
| Teva Pharmaceuticals USA, INC. | $31.78 | 2021-2022 | |
| Johnson & Johnson Health Care Systems INC. | $29.73 | 2023 | Opsumit |
| Resmed Corp | $29.38 | 2022-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $23.58 | 2019 | |
| Grifols USA, LLC | $23.13 | 2025 | Prolastin-C Liquid |
| Amgen INC. | $19.88 | 2025 | Tezspire |
| Merck Sharp & Dohme LLC | $19.79 | 2023 | Belsomra |
| Idorsia Pharmaceuticals US INC | $18.64 | 2023 | Quviviq |
| Pfizer INC. | $15.95 | 2021 | |
| Gilead Sciences, INC. | $15.46 | 2022 | |
| Inogen, INC. | $2.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Zolty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.